Devin Blass
Keine laufenden Positionen mehr
Profil
Devin Blass worked as Director-Commercial Program Manufacturing at Mesoblast, Inc., Head-Cell Manufacturing Operations at Bellicum Pharmaceuticals, Inc., and Vice President-Technical Operations at Talaris Therapeutics, Inc. He obtained an undergraduate degree from Texas State University.
Ehemalige bekannte Positionen von Devin Blass
| Unternehmen | Position | Ende |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Mesoblast, Inc.
 Mesoblast, Inc. Pharmaceuticals: MajorHealth Technology Mesoblast, Inc. manufactures and distributes biopharmaceutical products. It develops cellular medicines for under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The company was founded by Michael Schuster and Silviu Itescu in 2004 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
| TOURMALINE BIO, INC. | Chief Operating Officer | - |
Ausbildung von Devin Blass
| Texas State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Mesoblast, Inc.
Mesoblast, Inc. Pharmaceuticals: MajorHealth Technology Mesoblast, Inc. manufactures and distributes biopharmaceutical products. It develops cellular medicines for under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The company was founded by Michael Schuster and Silviu Itescu in 2004 and is headquartered in New York, NY. | Health Technology |
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Talaris Therapeutics, Inc.
 Talaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company, which engages in the development of allogeneic hematopoietic stem cell transplantation. The company was founded by Suzanne Ildstad on February 15, 2002 and is headquartered in Wellesley, MA. | Health Technology |
